Go to content
UR Home

Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

Gökbuget, Nicola ; Zugmaier, Gerhard ; Dombret, Hervé ; Stein, Anthony ; Bonifacio, Massimiliano ; Graux, Carlos ; Faul, Christoph ; Brüggemann, Monika ; Taylor, Kate ; Mergen, Noemi ; Reichle, Albrecht ; Horst, Heinz-August ; Havelange, Violaine ; Topp, Max S. ; Bargou, Ralf C.


Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE(R)immuno-oncotherapy, 15 mu g/m(2)/day for up to four 6-week cycles (4 weeks continuous infusion, 2 weeks off). Survival was evaluated for 110 ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons